Labat Africa (JSE:LAB) Accounts Payable & Accrued Expense: R327.2 Mil (As of Nov. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Labat Africa Accounts Payable & Accrued Expense?

Labat Africa JSE:LAB Accounts Payable & Accrued Expense is R327.2 Mil as of Nov. 2025. The stock has 8 warning signs investors should review.

Labat Africa's quarterly accounts payable & accrued expense increased from Nov. 2024 (R21.2 Mil) to May. 2025 (R335.3 Mil) but then declined from May. 2025 (R335.3 Mil) to Nov. 2025 (R327.2 Mil).

Labat Africa's annual accounts payable & accrued expense increased from May. 2023 (R60.9 Mil) to May. 2024 (R77.2 Mil) and increased from May. 2024 (R77.2 Mil) to May. 2025 (R335.3 Mil).

Labat Africa Accounts Payable & Accrued Expense Historical Data

* Premium members only.

The historical data trend for Labat Africa's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Labat Africa Accounts Payable & Accrued Expense Chart

Labat Africa Annual Data
Trend Feb15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 May23 May24 May25
Accounts Payable & Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.39 45.98 60.94 77.18 335.33

Labat Africa Semi-Annual Data
Aug15 Aug16 Feb17 Aug17 Feb18 Aug18 Feb19 Aug19 Feb20 Aug20 Feb21 Aug21 Feb22 Nov22 May23 Nov23 May24 Nov24 May25 Nov25
Accounts Payable & Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.96 77.18 21.24 335.33 327.16

Labat Africa Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

What does a Accounts Payable & Accrued Expense of R327.2 Mil mean?
Labat Africa (JSE:LAB) has a Accounts Payable & Accrued Expense of R327.2 Mil as of Nov. 2025. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Labat Africa and its competitors.
Is Labat Africa's Accounts Payable & Accrued Expense too high?
Labat Africa's current Accounts Payable & Accrued Expense is R327.2 Mil.
How does Labat Africa's Accounts Payable & Accrued Expense compare to ZTS and UTHR?
Labat Africa's Accounts Payable & Accrued Expense of R327.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable & Accrued Expense for a Drug Manufacturers company?
A good Accounts Payable & Accrued Expense depends on the Drug Manufacturers industry context. However, Accounts Payable & Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable & Accrued Expense mean?
A high Accounts Payable & Accrued Expense can signal that a stock is expensive relative to its fundamentals. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Labat Africa and its competitors. Labat Africa's current Accounts Payable & Accrued Expense is R327.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labat Africa stock overvalued right now?
Based on GuruFocus' analysis, Labat Africa (JSE:LAB) is currently considered Possible Value Trap. The stock's GF Value™ is R0.22, compared to a current price of R0.03 — trading 86.4% below its estimated fair value. The current Accounts Payable & Accrued Expense is R327.2 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable & Accrued Expense calculated?
Accounts Payable & Accrued Expense is calculated from a company's financial statements. For Labat Africa (JSE:LAB), the current Accounts Payable & Accrued Expense is R327.2 Mil as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Labat Africa Business Description

Other Exchanges LAO:Germany
Address 75 Maude StreetSandown, The Leonardo 14th Floor, Sandown, Johannesburg, GT, ZAF, 1709
Labat Africa Ltd is an investment holding company. Through its subsidiaries, the company operates in the following segments; Technology, Head office, and Healthcare. The Technology segment manufactures and distributes integrated circuits South African Micro - Electronic Systems. Head office operations provide management services, logistics and seeks further investment opportunities for the Group. The Healthcare segment generates maximum revenue for the company and focusses on medical cannabis industry in South Africa. Geographically, the company carries out its business operations in South Africa.